Status:
TERMINATED
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Lead Sponsor:
Medical University of Vienna
Conditions:
Macular Degeneration
Regional Blood Flow
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Age related macula degeneration is one of the most common sight threatening diseases of the elderly. The so called wet form of AMD is caused by choroidal neovascularisation (CNV) of pathological vesse...
Eligibility Criteria
Inclusion
- 40 subjects ≥ 50 years of age
- Subjects with all angiographic subtypes of neovascular wet AMD, already scheduled for intravitreal anti-VEGF therapy in one eye
- Good central or eccentric fixation
Exclusion
- History or previous Anti-VEGF therapy
- History or previous intravitreal injection with any drug
- Intraocular pressure ≥ 25
- Glaucoma
- History or presence of thromboembolic events
- Diabetes mellitus
- Blood donation during the previous 3 weeks
- Ametropy ≥ 6 dpt
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00709657
Start Date
March 1 2008
End Date
November 1 2011
Last Update
November 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria, 1090